Isomark was one of ten technology companies recognized at the inaugural Wisconsin Innovation Award ceremonies, which took place on August 26, 2014 in Madison, WI. The award ceremony was started to recognize innovative companies in Wisconsin. There is a tremendous amount of promising technology in Wisconsin. Over 150 companies applied for the awards. Isomark is truly honored to be one of the recipients. Here is the link to the full article.
In September 2013, Senator Tammy Baldwin and Isomark met to talk about Isomark, healthcare startups and HAIs (Healthcare-Associated Infections). It was a great discussion. After that meeting, Senator Baldwin was a part of a Senator Hearing on reducing HAIs. During the Hearing, she mentions Isomark as an example of cutting edge technology that could help give hospital staff and patients another tool to detect and treat HAIs. Here is the short clip where Senator Baldwin mentions Isomark: https://www.youtube.com/watch?v=8ZscucuiFWM And if you have some time on your hands, here is the full video of the Committee Hearing - U.S. Efforts to Reduce Healthcare-Associated Infections: Tuesday, September 24 2013, 10:00 AM http://www.help.senate.gov/hearings/hearing/?id=f456e2d1-5056-a032-5205-16c713b1418e (2 hours 25 minutes)
Click here to read Isomark's April 2014 Newsletter. Enjoy. Isomark's newsletters come out about four times per year. If you don't want to miss another Isomark newsletter, please sign-up to receive all the newsletters here: http://isomark.com/contact-us/. We promise to never spam you.
Medcity News published a great article on Isomark: Link to Article This Medcity article gave a nice summary of Isomark's technology and proof-of-concept study. The article then talked about our recent $280,000 investment and upcoming 110 patient study at the University of Wisconsin Hospital.
MADISON – The Wisconsin Alumni Research Foundation has invested $150,000 in Isomark LLC, funding that will be used by the Madison-based firm to help support a 110-patient study of the company’s non-invasive “Canary” breath analyzer. The device is intended to provide early warnings of potentially deadly patient infections. The WARF investment more than doubles $130,000 in private money raised by Isomark in recent months as part of its latest $750,000 funding round. The round will be used to support the study, which will take place at the UW Hospital and Clinics. “Isomark is a ready example of technology developed at the UW-Madison with potential for saving and improving lives worldwide,” said Michael Falk, general counsel for WARF. “Our investment will help move the company to its next stage and to…
Isomark was featured on the front page of the business section in the Wisconsin State Journal. The article talked about Isomark's successful first human clinical study at American Family Children's Hospital. The article also mentioned Isomark's road to commercialization which includes Isomark's 110 patient study at University of Wisconsin Hospital that will start in June 2014 and FDA clearance by 2017. It's a great article on Isomark. http://host.madison.com/business/technology/biotech/article_3b8d2401-b96a-59af-98f3-9e64b2cbfc61.html
Isomark and its scientific team were selected for the cover of the Journal of Analytical Atomic Spectrometry in their April 2014 edition. This is a great honor for Isomark and Isomark's CSO, Daniel Butz, PhD. It's not easy showing breath in a picture but it turned out great. Journal of Analytical Atomic Spectrometry, Front Cover, Volume 29, Number 4, April 2014
MADISON – A study of 17 mechanically ventilated pediatric patients, ranging in age from one month to nearly 18 years old, has demonstrated a link between breath carbon isotope “delta values” and inflammatory acute phase response. The results differentiated between healthy and infected patients. The study, conducted at the University of Wisconsin Hospitals and Clinics, examined the relationship between breath delta values and early diagnosis of Systemic Inflammatory Response Syndrome. The onset of SIRS, which occurs in 82 percent of patients admitted to pediatric intensive care units, can lead to sepsis. Sepsis, severe sepsis and septic shock are types of systemic infections caused by a micro-organism, such as bacteria or viruses, and may lead to organ dysfunction and death. Sepsis ranks as the most common cause of death of infants…
Isomark’s CSO, Daniel E. Butz, Shannon Casperson and Leah D. Whigman publish article: “The emerging role of carbon isotope ratio determination in health research and medical diagnostics.” Isomark’s Chief Scientific Officer, Daniel E. Butz, along with collaborators recently published an article discussing the role of the carbon isotope ratio to assist with medical and health research. The article was published in the Journal of Analytical Anatomic Spectrometry. The article discusses how isotopic signatures can monitor shifts in body metabolism, which can assist with determining health and disease status of patients. Here is a link to the article and abstract: http://pubs.rsc.org/en/content/articlelanding/2013/ja/c3ja50327e#!divAbstract
Madison, WI - Daniel Butz PhD of Isomark, LLC recently gave a presentation at the GeoMed 2013 Conference in Italy. His presentation, titled “Breath carbon isotope delta value may be a biomarker of catabolic inflammatory actute phase response in mechanically ventilated pediatric patients”, focused on technology developed at Isomark. The GeoMed 2013 conference was held to discuss advances in the use of natural stable isotope fractionation, which is affected by reactions taking place within the body. One example of research on isotope fractionation is in the varying efficiency of dietary uptake due to isotope fractionation. The conference’s goal was to create a new scientific community composed of biologists, physicians and geochemists. Dr. Butz is the Chief Scientific Officer of Isomark, LLC. His research focuses on the early detection of diseases…